STING1 and Aicardi-Goutieres syndrome: The proposed flare criteria may become useful but require validation in other interferonopathies including Aicardi-Goutières syndrome (AGS) and stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI) when treatments become available that achieve similar disease control to JAKis in CANDLE/PRAAS.